Results 71 to 80 of about 2,758 (199)
BMC NephrologyBackground The complement factor 5 (C5)-inhibitor eculizumab has been established as standard-of-care for the treatment of atypical hemolytic uremic syndrome (aHUS).
Kristina Schönfelder +8 more
doaj +1 more source
Mild clinical course of covid-19 in 3 patients receiving therapeutic monoclonal antibodies targeting c5 complement for hematologic disorders [PDF]
, 2020 © Am J Case Rep, 2020. Objective: Rare co-existance of disease or pathology Background: Patients receiving immunosuppressive therapies might be more susceptible to COVID-19.
Araten, D. J. +5 more
core +2 more sources
eJHaem, Volume 7, Issue 2, April 2026.ABSTRACT A 28‐year‐old male with paroxysmal nocturnal haemoglobinuria (PNH) presented with headache, nasal bridge discomfort and haemoglobinuria. He developed a macular‐papular rash which rapidly progressed into purpura, necrosis and peri‐orbital oedema. Investigations demonstrated severe haemolytic anaemia and acute parvovirus B19 infection.
Louise J. Potter +9 more
wiley +1 more source
eJHaem, Volume 7, Issue 2, April 2026.ABSTRACT Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life‐threatening disorder characterized by complement‐mediated hemolysis. Crovalimab, a novel anti‐C5 monoclonal antibody, may offer a more convenient alternative to current therapies, highlighting the need for a comprehensive analysis of its efficacy and safety.
Hammad Javaid +11 more
wiley +1 more source
Usage of Newer Immunotherapies in Myasthenic Crisis – A Review of the Literature [PDF]
non
Dang, Johnny, Li, Yuebing, Uysal, Sanem
core +2 more sources
Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy [PDF]
Complement inhibitors are the mainstay of paroxysmal nocturnal hemoglobinuria (PNH) treatment. The anti-C5 monoclonal antibody eculizumab was the first treatment to improve hemolysis, thrombotic risk, and survival in PNH although at the price of a life ...
Fattizzo, Bruno, Versino, Francesco
core +1 more source
Examining Consistency Across NICE Single Technology Appraisals:A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria [PDF]
In 2024, the National Institute for Health and Care Excellence (NICE) recommended two new health technologies for paroxysmal nocturnal haemoglobinuria. This review systematically compares the clinical and cost-effectiveness evidence considered within the
Donoghue, Jeremiah +6 more
core +1 more source
European Journal of Neurology, Volume 33, Issue 3, March 2026.In our real‐world study of 276 patients, rituximab and inebilizumab demonstrated comparable efficacy in the medium term but differed in their safety profiles, with a significantly higher incidence of infusion‐related reactions observed in the rituximab group.
Ying Cui +11 more
wiley +1 more source
European Journal of Neurology, Volume 33, Issue 3, March 2026.Conceptual framework supporting Minimal Symptom Expression (MSE) as a patient‐centric treatment goal in generalized myasthenia gravis. Guidelines prioritize minimal manifestations (MM) or better (MGFA‐PIS); MM is clinician‐judgment based and not instrument‐defined. MSE (MG‐ADL 0‐1) is standardized, actionable, and widely used. Across Phase III programs
Andreas Meisel +5 more
wiley +1 more source